Profound Medical (OTCQX:PRFMF; TSXV:PRN) has successfully completed the first sale of a TULSA-PRO system in Finland to the Turku University Hospital, in collaboration with Royal Philips, who is working in partnership with Profound to commercialize the TULSA-PRO system in Europe.Read More
RBC Capital Markets downgraded Concordia International (NASDAQ:CXRX; TSX:CXR) to “underperform” from “sector perform” and cut its price target to $1 from $2.50. The stock closed at $2.38 on Dec. 6.Read More
Profound Medical (TSX-V:PRN) has received Frost & Sullivan’s 2016 European Prostate Ablation Systems New Product Innovation Award for its TULSA-PRO system.
TULSA-PRO, which received CE Mark approval in April 2016, combines real-time MRI with transurethral, robotically driven therapeutic ultrasound and closed-loop thermal feedback control designed to provide precise ablation of the prostate, while simultaneously protecting critical surrounding anatomy from potential side effects.Read More
Rodman & Renshaw has initiated coverage of LabStyle Innovations (NASDAQ:DRIO) with a “buy” rating and $12 price target. The stock closed at $5.40 on Friday.
LabStyle is an emerging digital health company focused on the monitoring and management of diabetes.Read More
Canaccord Genuity has downgraded AngioDynamics (NASDAQ:ANGO) to “hold” from “buy” and reduced its price target to $13 from $14.50, following the abrupt departure of CEO, Joe DeVivo, “which we think will heighten investor concern near term, and increase uncertainty.” The stock closed at $12.14 on Monday.
“What’s more, this change compounds myriad existing challenges that have produced sluggish and inconsistent performance in the business over the past year,” writes analyst Jason Mills.Read More